Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Clinical trial NCT05927857 · RECRUITING

Trial details

NCT number: NCT05927857
Sponsor: National Health Research Institutes, Taiwan
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Gastric Adenocarcinoma Second Line Chemotherapy

Start date: 2024-04-01
Primary completion: 2027-12-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.